| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Principal payments on finance lease liabilities | 208 | 208 |
| Net cash used in financing activities | -128 | -123 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 34,249 | 13,278 |
| Cash and cash equivalents at beginning of period | 16,518 | - |
| Cash and cash equivalents at end of period | 50,767 | - |
Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Inc (PRLD)